Skip to content
Home/Companies/Biotech/Vivet
Vivet

Vivet

Biotech·France·Active·7yr hold
Entry
2019
Hold
7yr
Status
Active

Who owns Vivet?

Vivet is a French Biotech company, currently owned by Eurazeo since 2019.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Eurazeo
Investor
Eurazeo
Kurma Biofund III · 2017 · Healthcare

Key facts

HQFrance
SectorBiotech
Websitewww.vivet-therapeutics.com

More from Kurma Biofund III

Other portfolio companies in the same fund.

ImCheck
ImCheck
3.0xExited 2025
BiotechFrance· 2020
to Ipsen
Amolyt Pharma
Amolyt Pharma
4.0xExited 2024
BiotechFrance· 2019
to AstraZeneca
Ermium
Ermium
Active
BiotechFrance· 2019
IO Biotech
IO Biotech
Active
BiotechDenmark· 2019
Pharvaris
Pharvaris
Active
BiotechNetherlands· 2019
Orphazyme
Orphazyme
Active
BiotechDenmark· 2017

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Vivet?

Vivet is currently owned by Eurazeo, through Kurma Biofund III, since 2019.

When did Eurazeo acquire Vivet?

Eurazeo acquired Vivet in 2019.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue